 NEW YORK, July 27, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, announced today top-line results of the human abuse potential HAP study with REL-1017, a novel NMDA receptor NMDAR channel blocker and the companys lead candidate in Phase 3 development for the treatment major depressive disorder MDD. Top-line results showed that all three doses of REL-1017 25 mg, 75 mg and 150 mg, the therapeutic, supratherapeutic and maximum tolerated doses, respectively tested in recreational opioid users, demonstrated a highly statistically significant difference vs. 